Lipid nanoparticles, or LNPs, best known as the delivery vehicle for the COVID-19 mRNA vaccines received by billions of people, are now at the center of a much larger medical revolution. Researchers ...

Since the COVID-19 pandemic, mRNA vaccines have gained attention as a next-generation pharmaceutical technology. mRNA therapeutics work by delivering genetic instructions that enable cells to produce ...

Read more about Future pandemics may be fought faster with mRNA and advanced vaccine platforms on Devdiscourse ...

Right before BioNTech was due to announce its 2025 results, the company’s co‑founders, Ugur Sahin and Özlem Türeci, revealed they would leave the company to focus on developing next‑generation mRNA ...

The co-founders of vaccine maker BioNTech are stepping down to launch a venture focused on next-generation messenger RNA ...

Cell-to-cell communication is essential throughout all forms and stages of life, and many communication mechanisms are well studied. However, over the past few years, scientists have found increasing ...

BioNTech's co-founders Ugur Sahin and Oezlem Tuereci plan to leave the company by 2026 to establish a new venture focused on mRNA technology. While ensuring BioNTech's existing operations continue ...

In addition to advancing the seasonal influenza vaccines market, the potential FDA approval of mRNA-1010 will also stake Moderna’s claim in the market.

Researchers developed an mRNA delivery system designed to improve embryo implantation. This approach could enhance ART outcomes and address uterine-factor infertility, with pre-clinical studies ...